Results 241 to 250 of about 488,286 (382)
Aims The aim of this study was to determine the purpose and use of physical examination (PE) in phase 3 and 4 drug interventional clinical trials within type 2 diabetes mellitus. Methods A total of 226 clinical trial protocols identified from the ClinicalTrials.gov database were systematically reviewed by five researchers.
Julia Kopanz +9 more
wiley +1 more source
Open-Label-Placebos can reduce pain, but not indigestion during gluten challenge in chronic pain patients. [PDF]
Paschke-Dahl L, Klinger R.
europepmc +1 more source
AZD0449, an inhaled JAK1 inhibitor, in healthy participants and patients with mild asthma
Aims Inhaled corticosteroids (ICS) plus bronchodilator are recommended for the treatment of asthma. Targeting the JAK1‐dependent pathway may be an alternative for asthma management in patients with incomplete response to ICS. The aim of this study was to investigate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of AZD0449, a
Anna Lundahl +11 more
wiley +1 more source
Capuride Versus Methyprylon and Placebo in Treating Sleeplessness Due to Presurgical Anxiety
Frank J. Tornetta
openalex +1 more source
Enalapril in patients with chronic heart failure: a placebo-controlled, randomized, double-blind study. [PDF]
D. N. Sharpe +3 more
openalex +1 more source
Problem setting The emergence of therapeutic proteins has coincided with an increase of acute adverse immunostimulation (AIS). AIS has occured in clinical trials despite compliance with regulatory guidelines on preclinical evaluation and its incidence is anticipated to increase even further.
Juliette A. van den Noort +8 more
wiley +1 more source
Placebos in medicine: medical paradoxes need disentangling [PDF]
Di Blasi, Zelda, Reilly, David
core +1 more source
Treatment of acute cerebral infarction with a choline precursor in a multicenter double-blind placebo-controlled study. [PDF]
Yuichi Tazaki +7 more
openalex +1 more source
Ileal bile acid transporter inhibitors (IBATi), including maralixibat and odevixibat, are a novel approach to the treatment of paediatric cholestatic liver diseases, such as Alagille syndrome (ALGS) and different forms of progressive familial intrahepatic cholestasis (PFIC).
Alise D. E. de Groot +5 more
wiley +1 more source

